The little-known 'pension scandal' that has been going on for 30 years
Hundreds of thousands of pensioners across the UK are facing a similar problem. They have been fighting for nearly 30 years to have their pension savings increased in line with inflation - which their ex-employers are not legally required to do.
In the last year, Patricia Kennedy and her fellow campaigners have written to 195 MPs, hoping to finally end their 30-year battle for what they claim to be a pension scandal.
Kennedy is part of the HPPA & Alliance Pension Justice campaign, representing thousands of pensioners in their seventies and eighties who worked for companies owned by the Hewlett Packard Enterprise and have not seen their pension increase since 1997.
Estimates place the number of people directly affected by the indexation at between 500,000 and 800,000 pensioners, but Kennedy thinks the figure could be even higher.
'We believe that there are between 750,000 and 1.8m pensioners in the UK whose pension values have significantly eroded and face an increasingly bleak future of zero increases," Kennedy, a former manager at Hewlett Packard Enterprise in Scotland and campaigner from the group, told Yahoo News.
It has been close to 30 years since the group first received notice that their pension funds would plummet, but Kennedy is still dogged in her determination, writing to over 100 MPs this year alone and meeting with pensions minister Torsten Bell to move the group's case forward.
For a number of workers she represents, the average annual pension for a UK retiree from this time is approximately £9,700.
Meanwhile, the profits at her former company stood at $500m in 2024.
Kennedy said: 'It's given that it was mandated by our employers at the time that we or I as an employee must contribute to the pension fund.
'Is it not reasonable that I or pensioners should also have the statutory right to share in the distribution of any surplus almost three decades later.
'It's been like a forced loan. They've had our money for all of this time and we have never been able to share in any yield.'
What is happened pre-1997 pensions?
Before 1997, there was no legal requirement in the UK for defined benefit (DB) occupational pension schemes to increase pensions in payment each year in line with inflation.
After the brazen theft of pension fund assets by media tycoon Robert Maxwell in the late 1980s and early 1990s, the government introduced The Pensions Act 1995, with the aim of protecting pension savers.
But as the scheme only protected mandated statutory indexation of pensions from April 1997 onward, increasing pensions earlier than this date was at the discretion of a savers' employer.
While many employers opted to increase pensions pre-1997 inline with inflation, a significant number didn't – and still haven't to this day.
Anyone drawing a defined benefit pension since before 1997 is likely at least 70, and often considerably older, especially given the rapid closures to new entrants and accrual since the mid-2000s.
By doing some quick maths, it's worth noting that someone aged 55 in 1997 is now 83 in 2025.
It also means that for many workers affected, their average pension is now worth just £9,700.
'It's very distressing'
Caroline Emery joined the team at American Express in 1985.
Emery won multiple awards during her time at the organisation, becoming a VP in marketing for the company before she moved to new pastures in 2012.
Now, she is working alongside former colleagues under the name Amex UK Pensioners Justice.
The campaign group estimates 5000 Amex employees are affected by the pre-1997 indexation.
Emery told Yahoo News: 'American Express has not provided discretionary increases for over 11 years. When I began my pension, there was a documented pattern of such increases until 2014. However, following that, all increases stopped altogether.
"The lack of clear communication regarding the cessation of discretionary increases from 2015 has contributed to pensioners confusion and financial distress surrounding their pension entitlements.'
While Emery's pension is divided over a number of pots, she is one of the lucky ones.
She told Yahoo News: 'It's very distressing when you hear about the dire straits some of these people are now in financially.
'One man we have supported, who lives in Brighton, posted on the group asking if people could donate so he could afford to buy himself a mobility scooter.
'We were all more than happy to contribute, but he was promised a secure pension. He shouldn't be in a position where he's had to ask for that.'
'It's been like a forced loan'
There is no precise, published figure for the exact number of companies which have opted not to increase pre-1997 pensions in line with inflation, but available evidence shows that the problem is widespread across the UK corporate sector, involving dozens – if not hundreds – of medium and large employers.
According to the latest data and parliamentary reports, two-thirds of DB schemes are permitted by their rules to provide discretionary benefit increases for pre-1997 service.
Of these, just under a third – 32% – have provided an increase in the past three years, and just 15% of those increases applied to pre-1997 benefits.
A lack of understanding of the UK pensions system could also put these workers at predominantly American companies at a disadvantage.
"The American pensions system is very different to ours," Emery said.
"There's this idea that if the company doesn't pay to top up the pensions, the pension is just going to get paid by the state."
High hopes
Campaigners like Kennedy and Emery had high hopes for this year's Pension Schemes Bill.
After meeting with pensions minister Torsten Bell in March, the group were told 'we have not forgotten you, and your situation is very much being discussed at the highest levels.'
But when the Pension Schemes Bill was first submitted to parliament, this issue had not made the bill – and if anything, the campaigners believe the legislation could make things worse.
Schemes with substantial surpluses may now see it as easier to return funds to sponsoring employers rather than address the long-standing claimed unfairness affecting older pensioners.
Kennedy told Yahoo News: 'The new legislation does not give us the power or there is no requirement to share any of the surplus with us.
'There is simply no requirement to share it with the people whose money it was.'
The government has launched a new Pensions Commission on 21 July, but there is no explicit mention that it will specifically examine the issue of pre-1997 indexation for defined benefit pensions.
While the government may be burying its head in the sand, just last week, the work and pensions committee issued a stark warning that pensioners are dying in poverty and without justice.
Speaking to Liz Kendall on 16 July, the group grilled the secretary of state on the government's delay in rolling out compensation.
While Kendall insisted the pensions minister was working to identify the pensioners, she also added compensating those affected 'would have wider implications for the public finances'.
'How can we justify this to them? They're in their late 70s and 80s now,' committee chair Debbie Abrahams said.
'They are dying by the day. The decency of humanity means we need to stand by them.
'It will cost the government £133m over the next ten years, against £14bn in reserves to fulfil the role of the pension protection fund. I'll just leave it at that.'
An Amex spokesperson told Yahoo News: "American Express fully complies with all its pension obligations to current and former colleagues and will continue to do so in the future. The Company annually reviews whether a discretionary increase will be awarded in respect of pre-1997 defined benefit pensions."
A HPE spokesperson told Yahoo News: 'HPE is committed to satisfying all of its responsibilities to both current and former team members. The decision on whether to grant discretionary increases to relevant pensioners is given careful consideration and is made based on a number of factors. It is reviewed on an annual basis.'
A DWP spokesperson said: 'We understand the impact this is having on members of these schemes, which is why we are continuing to work to find a solution.
'Any changes in this area would have significant implications on public finances, which is why we need to consider it thoroughly.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Trump tariffs live updates: US-EU agreement announced. China truce extension expected.
President Trump and European Commission President Ursula von der Leyen announced Sunday that the US and EU had agreed to the framework of a trade deal that included a baseline tariff rate of 15% on EU goods imported into the US. Trump, , speaking after negotiations in Scotland on Sunday, called the deal 'the biggest of them all,' while von der Leyen said that "15% is not to be underestimated, but it is the best we could get." Other details of the framework are still being confirmed. Meanwhile, the South China Morning Post, a Hong Kong-based English-language newspaper, reported that "Beijing and Washington are expected to extend their tariff truce by another three months at trade talks in Stockholm beginning on Monday." On Friday, Trump said that letters dictating tariff rates for over 200 countries would go out soon while his administration works to clinch deals with larger trade partners. Trump said the US hasn't had a "lot of luck" with Canada and suggested he may impose threatened 35% levies on goods not covered by the US-Canada-Mexico trade agreement. Last week, President Trump touted a deal with Japan that included a $550 billion investment in the US and a 15% tariff on goods imported into the US from Japan. On Saturday, Japanese trade negotiator Ryosei Akazawa suggested the money could be used to help finance an unnamed Taiwanese chipmaker building plants in the US. "For example, if a Taiwanese chipmaker builds a plant in the US and uses Japanese components or tailors its products to meet Japanese needs, that's fine too," he said. In March, Taiwan's TSMC announced a $100 billion investment in the US, on top of plans to build three plants in Arizona, one of which is already operating. In any case, the Japan trade deal may have set a precedent for Trump's new baseline tariff rate. Trump said tariffs would range from 15% to 50%, with tougher partners facing higher rates. That's a step up from the 10% baseline duties currently in effect.. Read more: What Trump's tariffs mean for the economy and your wallet Here are the latest updates as the policy reverberates around the world. EU-US trade deal undermines bloc claims of negotiating power The US-EU trade deal has the potential to roll back months of EU posturing as a leading global economic force. This is based on the argument that the bloc has been pushed into accepting a "least-worst" deal after failing to bring suitable leverage to the trade table. Reuters reports: Read more here. Why Big Alcohol needs US tariff relief in five charts European Union wine and spirits producers could emerge as one of the few winners in the US-EU trade deal which was agreed on Sunday. Reuters reports: Shares in Pernod, Diageo and Campari initially rose in early trade. But they stood 1.3%, 0.4% and 0.3% lower by 0707 GMT. Shares in Remy fell 2.2%. Alcohol is among the EU's top exports to the United States, worth about $10.5 billion in 2024, according to Eurostat data, with certain products like Remy Martin cognac and champagne required to be produced in specific European regions. The United States accounts for about 18% of exports for another exclusively French product, champagne. For cognac makers, the U.S. tariffs represent a fresh challenge after producers of the drink managed this month to avert the threat of duties of up to around 35% from China. For Spanish and Italian wines, around 14% and 24% of total exports, respectively, are sold in the United States. Stock in focus after US/EU trade deal: ASML Semiconductor play ASML (ASML) getting a lot of mentions on the Street this morning as a winner from the US/EU trade deal. Shares are up nearly 5% in pre-market trading. I would note ASML just a week ago issued weak guidance that hammered the stock, so be mindful of that. Here's what JP Morgan had to say this morning: "ASML had indicated in its Q2 results that it saw hesitation (and thus lack of orders) from customers to order tools for their new US fabs due to the risk of tariffs on semiconductor equipment. If this information from the US on zero tariffs on semiconductor equipment is correct then this would be very positive for ASML in particular, but also for VAT. Other semiconductor equipment companies in Europe, such as ASM International ( manufacture their tools outside the EU and thus deals with countries such as Singapore, Malaysia and the US will be important for those companies." Donald Trump freezes export controls to secure trade deal with China The FT reported on Monday that President Donald Trump has frozen restrictions on technology exports to China in order to avoid hurting trade talks with Beijing and to help secure a meeting between Trump and President Xi Jinping this year, according to people familiar with the matter. The US Commerce Department's Bureau of Industry and Security, which is in charge of export controls, has been advised to avoid tough moves on China, according to eight people, including current and former US officials. The US and China are due to meet in Stockholm on Monday for a third round of trade talks following previous meetings in Geneva and London. The FT reports: Read more here (subscription required). Heineken cheers EU-US trade deal as tariff problems grow Dutch brewer Heineken (HKHHY, said on Monday that it welcomed the trade deal between the European Union and the US and that it was weighing all options to deal with growing tariff challenges in the long term, including shifting manufacturing. Reuters reports: Read more here. Japan expects 1%-2% of $550 billion US fund to be investment Japan confirmed that only a small part, just 1% to 2%, of the $550 billion deal with the US will be actual investment. Most of the money will be in the form of loans, according to Japan's trade negotiator Ryosei Akazawa. Akazawa said that Tokyo will save roughly $68 billion through lower tariff rates in its deal with the US. The details revealed by Akazawa on Saturday via an interview with public broadcaster NHK, suggest the Japanese may end up giving up much less than at first glance. The $550 billion investment framework combines loans, investments and loan guarantees provided by financial institutions backed by the Japanese government. Bloomberg News reports: Read more here. VW's Audi cuts full-year outlook, citing tariffs and restructuring Following Volkswagen's ( VWAGY) guidance cut last week, the German carmakers premium brand Audi has also cut its full-year guidance, citing the impact of higher US import tariffs and restructuring expenses. Reuters reports: Read more here. Italy's Meloni awaiting details but says trade deal 'positive' As many of the specifics of the trade deal between the EU and US remained unclear Sunday, at least one European Union leader said she was awaiting more information before passing judgment on it. Italy's Prime Minister Giorgia Meloni called it "positive' that he agreement had been reached, but wanted to see the details, Reuters reports: Read more here. European Commission President Ursula von der Leyen noted that there isn't yet a specific US-EU agreement on tariffs regarding wine and spirits between the two trading partners, among other unsettled details, and the Distilled Spirits Council of the United States is lobbying for an amicable resolution. "We are optimistic that in the days ahead this positive meeting and agreement will lead to a return to zero-for-zero tariffs for U.S. and EU spirits products, which will benefit not only our nation's distillers, but also the American workers and farmers who support them from grain to glass," the trade association's president and CEO Chris Swonger said in a statement provided to Yahoo Finance. "For more than 20 years, large and small distilleries across the U.S. have flourished under a tariff-free relationship with the EU, our largest export market. It's time to get back to toasts not tariffs.' Pharma tariffs still a point of disagreement in EU-US trade deal The trade deal ironed out between the EU and the US on Sunday has more than few wrinkles remaining, chief among them: What the levy on pharmaceuticals will be. Bloomberg reports: Read more here. Trump deal with Europe underlines new standard of (at least) 15% tariffs From YF's Ben Werschkul: Read more here. EU's von der Leyen provides some detail on new deal PRESTWICK, Scotland (Reuters) — European Commission President Ursula von der Leyen on Sunday said a U.S. baseline tariff rate of 15% on imported EU goods would apply to cars, semiconductors and pharmaceutical goods. She also said that a zero-for-zero tariff rate had been agreed for certain strategic products, including aircraft and aircraft parts, certain chemicals, and certain generic drugs. No decision had been taken on a rate for wine and spirits, she added. "Today's deal creates certainty in uncertain times, delivers stability and predictability," von der Leyen told reporters before leaving Scotland EU-US trade agreement reactions Reuters gathered some market commentary after the US and EU announced the framework of a trade deal: Read more here. EU-US trade agreement preliminary details Here are some Bloomberg terminal headlines with various details on the agreement reached between President Trump and European Commission President Ursula von der Leyen: *TRUMP: WE HAVE REACHED A DEAL WITH EU *TRUMP: EU WILL AGREE TO BUY US $750B WORTH OF ENERGY *TRUMP: EU WILL AGREE TO INVEST $600B MORE THAN PREVIOUSLY IN US *EU'S VON DER LEYEN: TREADE DEAL WITH US WILL BRING STABILITY *VON DER LEYEN: AGREED TO 15% ACROSS THE BOARD TARIFFS The asserted details of the framework are not yet fully confirmed. SCMP reports China-US another 90-day tariff extension The South China Morning Post (SCMP) reported that "Beijing and Washington are expected to extend their tariff truce by another three months at trade talks in Stockholm beginning on Monday." More from the Hong-Kong-based SCMP: Read more here. Lutnick: EU has to offer Trump 'a good enough deal' to avoid 30% tariffs As President Trump prepares for a planned meeting about tariffs with European Commission President Ursula von der Leyen, Commerce Secretary Howard Lutnick said Sunday that the European Union has to open its markets for US exports if it wants to convince Trump to reduce the 30% tariff he's threatened to put in place August 1. Reuters reports Lutnick said the EU appeared to want to make a deal: On Friday, Trump said the odds of a trade deal with the EU were about "50-50," even as negotiators from both sides expressed optimism. Read more here. LG says consumers rushed to buy appliances ahead of tariffs Tariffs remain a key concern for South Korean appliance maker LG Electronics ( The company said that if President Trump's blanket tariffs take effect on Aug. 1, it will adjust prices and move some production to its plants in Mexico and the US. LG produces its products worldwide, particularly in South Korea, China, and Vietnam. On Aug. 1, imports from South Korea face a 25% tariff, while those from Vietnam face a 20% tariff. Imports from China are estimated to face tariffs of roughly 50%, though that could change after US and Chinese officials meet in Sweden for the next round of trade talks. According to LG, consumers rushed to purchase items in the first half of the year to avoid tariffs. Still, the company's net profit fell 3.1% in Q2 as operating costs increased. "Some consumers have been rushing to make purchases before the tariffs take effect," an executive said on the earnings call. "In the first half of 2025, we achieved approximately 3% growth year over year, higher than the market demand with new product launches and efficient sales operations, continuing to strengthen our market presence." But that pull-forward in demand could signal weakness ahead in the months to come if trade tensions escalate again. "A rise in product costs driven by the 50% tariff on steel and reciprocal tariffs that are set to be applied in the latter half of the year could translate into greater uncertainties for the market price," the executive said. "Additionally, shifts in the US government's trade policies and weakening consumer sentiment cast doubt on the demand outlook for home appliances." This isn't the first time LG has grappled with US protectionist policies. In 2018, during Trump's first term, washing machine prices rose when Trump targeted the industry with tariffs. Japan says $550 billion investment could finance Taiwanese chipmaker in US The $550 billion President Trump said Japan gave to the US "to lower their tariffs a little bit," could be used to help finance a Taiwanese chipmaker building plants in the US, the Associated Press reported Saturday. Trump on Thursday called the $550 billion "seed money" and that 90% of profits from the money invested would go to the US. "It's not a loan or anything, it's a signing bonus," Trump said. Read more here. More cracks form in the US-Japan trade agreement We detailed earlier (keep scrolling) some initial, if gentle, pushback from the Japanese side on the US portrayal of the countries' trade deal. The Financial Times has a good, detailed look at some of the "cracks" forming: Read more here (subscription required). EU head to meet with Trump this weekend in bid to clinch deal Bloomberg reports that European Commission President Ursula von der Leyen will meet with President Trump this weekend as he travels to his golf club in Scotland in a bid to secure a trade deal. The meeting will come as the two sides race to secure a deal ahead of next Friday — Trump's self-imposed deadline for 30% tariffs on EU goods to kick in. On Friday, Trump put the odds of a deal at "50-50." From the report: The US-EU trade deal has the potential to roll back months of EU posturing as a leading global economic force. This is based on the argument that the bloc has been pushed into accepting a "least-worst" deal after failing to bring suitable leverage to the trade table. Reuters reports: Read more here. Why Big Alcohol needs US tariff relief in five charts European Union wine and spirits producers could emerge as one of the few winners in the US-EU trade deal which was agreed on Sunday. Reuters reports: Shares in Pernod, Diageo and Campari initially rose in early trade. But they stood 1.3%, 0.4% and 0.3% lower by 0707 GMT. Shares in Remy fell 2.2%. Alcohol is among the EU's top exports to the United States, worth about $10.5 billion in 2024, according to Eurostat data, with certain products like Remy Martin cognac and champagne required to be produced in specific European regions. The United States accounts for about 18% of exports for another exclusively French product, champagne. For cognac makers, the U.S. tariffs represent a fresh challenge after producers of the drink managed this month to avert the threat of duties of up to around 35% from China. For Spanish and Italian wines, around 14% and 24% of total exports, respectively, are sold in the United States. European Union wine and spirits producers could emerge as one of the few winners in the US-EU trade deal which was agreed on Sunday. Reuters reports: Shares in Pernod, Diageo and Campari initially rose in early trade. But they stood 1.3%, 0.4% and 0.3% lower by 0707 GMT. Shares in Remy fell 2.2%. Alcohol is among the EU's top exports to the United States, worth about $10.5 billion in 2024, according to Eurostat data, with certain products like Remy Martin cognac and champagne required to be produced in specific European regions. The United States accounts for about 18% of exports for another exclusively French product, champagne. For cognac makers, the U.S. tariffs represent a fresh challenge after producers of the drink managed this month to avert the threat of duties of up to around 35% from China. For Spanish and Italian wines, around 14% and 24% of total exports, respectively, are sold in the United States. Stock in focus after US/EU trade deal: ASML Semiconductor play ASML (ASML) getting a lot of mentions on the Street this morning as a winner from the US/EU trade deal. Shares are up nearly 5% in pre-market trading. I would note ASML just a week ago issued weak guidance that hammered the stock, so be mindful of that. Here's what JP Morgan had to say this morning: "ASML had indicated in its Q2 results that it saw hesitation (and thus lack of orders) from customers to order tools for their new US fabs due to the risk of tariffs on semiconductor equipment. If this information from the US on zero tariffs on semiconductor equipment is correct then this would be very positive for ASML in particular, but also for VAT. Other semiconductor equipment companies in Europe, such as ASM International ( manufacture their tools outside the EU and thus deals with countries such as Singapore, Malaysia and the US will be important for those companies." Semiconductor play ASML (ASML) getting a lot of mentions on the Street this morning as a winner from the US/EU trade deal. Shares are up nearly 5% in pre-market trading. I would note ASML just a week ago issued weak guidance that hammered the stock, so be mindful of that. Here's what JP Morgan had to say this morning: "ASML had indicated in its Q2 results that it saw hesitation (and thus lack of orders) from customers to order tools for their new US fabs due to the risk of tariffs on semiconductor equipment. If this information from the US on zero tariffs on semiconductor equipment is correct then this would be very positive for ASML in particular, but also for VAT. Other semiconductor equipment companies in Europe, such as ASM International ( manufacture their tools outside the EU and thus deals with countries such as Singapore, Malaysia and the US will be important for those companies." Donald Trump freezes export controls to secure trade deal with China The FT reported on Monday that President Donald Trump has frozen restrictions on technology exports to China in order to avoid hurting trade talks with Beijing and to help secure a meeting between Trump and President Xi Jinping this year, according to people familiar with the matter. The US Commerce Department's Bureau of Industry and Security, which is in charge of export controls, has been advised to avoid tough moves on China, according to eight people, including current and former US officials. The US and China are due to meet in Stockholm on Monday for a third round of trade talks following previous meetings in Geneva and London. The FT reports: Read more here (subscription required). The FT reported on Monday that President Donald Trump has frozen restrictions on technology exports to China in order to avoid hurting trade talks with Beijing and to help secure a meeting between Trump and President Xi Jinping this year, according to people familiar with the matter. The US Commerce Department's Bureau of Industry and Security, which is in charge of export controls, has been advised to avoid tough moves on China, according to eight people, including current and former US officials. The US and China are due to meet in Stockholm on Monday for a third round of trade talks following previous meetings in Geneva and London. The FT reports: Read more here (subscription required). Heineken cheers EU-US trade deal as tariff problems grow Dutch brewer Heineken (HKHHY, said on Monday that it welcomed the trade deal between the European Union and the US and that it was weighing all options to deal with growing tariff challenges in the long term, including shifting manufacturing. Reuters reports: Read more here. Dutch brewer Heineken (HKHHY, said on Monday that it welcomed the trade deal between the European Union and the US and that it was weighing all options to deal with growing tariff challenges in the long term, including shifting manufacturing. Reuters reports: Read more here. Japan expects 1%-2% of $550 billion US fund to be investment Japan confirmed that only a small part, just 1% to 2%, of the $550 billion deal with the US will be actual investment. Most of the money will be in the form of loans, according to Japan's trade negotiator Ryosei Akazawa. Akazawa said that Tokyo will save roughly $68 billion through lower tariff rates in its deal with the US. The details revealed by Akazawa on Saturday via an interview with public broadcaster NHK, suggest the Japanese may end up giving up much less than at first glance. The $550 billion investment framework combines loans, investments and loan guarantees provided by financial institutions backed by the Japanese government. Bloomberg News reports: Read more here. Japan confirmed that only a small part, just 1% to 2%, of the $550 billion deal with the US will be actual investment. Most of the money will be in the form of loans, according to Japan's trade negotiator Ryosei Akazawa. Akazawa said that Tokyo will save roughly $68 billion through lower tariff rates in its deal with the US. The details revealed by Akazawa on Saturday via an interview with public broadcaster NHK, suggest the Japanese may end up giving up much less than at first glance. The $550 billion investment framework combines loans, investments and loan guarantees provided by financial institutions backed by the Japanese government. Bloomberg News reports: Read more here. VW's Audi cuts full-year outlook, citing tariffs and restructuring Following Volkswagen's ( VWAGY) guidance cut last week, the German carmakers premium brand Audi has also cut its full-year guidance, citing the impact of higher US import tariffs and restructuring expenses. Reuters reports: Read more here. Following Volkswagen's ( VWAGY) guidance cut last week, the German carmakers premium brand Audi has also cut its full-year guidance, citing the impact of higher US import tariffs and restructuring expenses. Reuters reports: Read more here. Italy's Meloni awaiting details but says trade deal 'positive' As many of the specifics of the trade deal between the EU and US remained unclear Sunday, at least one European Union leader said she was awaiting more information before passing judgment on it. Italy's Prime Minister Giorgia Meloni called it "positive' that he agreement had been reached, but wanted to see the details, Reuters reports: Read more here. As many of the specifics of the trade deal between the EU and US remained unclear Sunday, at least one European Union leader said she was awaiting more information before passing judgment on it. Italy's Prime Minister Giorgia Meloni called it "positive' that he agreement had been reached, but wanted to see the details, Reuters reports: Read more here. European Commission President Ursula von der Leyen noted that there isn't yet a specific US-EU agreement on tariffs regarding wine and spirits between the two trading partners, among other unsettled details, and the Distilled Spirits Council of the United States is lobbying for an amicable resolution. "We are optimistic that in the days ahead this positive meeting and agreement will lead to a return to zero-for-zero tariffs for U.S. and EU spirits products, which will benefit not only our nation's distillers, but also the American workers and farmers who support them from grain to glass," the trade association's president and CEO Chris Swonger said in a statement provided to Yahoo Finance. "For more than 20 years, large and small distilleries across the U.S. have flourished under a tariff-free relationship with the EU, our largest export market. It's time to get back to toasts not tariffs.' European Commission President Ursula von der Leyen noted that there isn't yet a specific US-EU agreement on tariffs regarding wine and spirits between the two trading partners, among other unsettled details, and the Distilled Spirits Council of the United States is lobbying for an amicable resolution. "We are optimistic that in the days ahead this positive meeting and agreement will lead to a return to zero-for-zero tariffs for U.S. and EU spirits products, which will benefit not only our nation's distillers, but also the American workers and farmers who support them from grain to glass," the trade association's president and CEO Chris Swonger said in a statement provided to Yahoo Finance. "For more than 20 years, large and small distilleries across the U.S. have flourished under a tariff-free relationship with the EU, our largest export market. It's time to get back to toasts not tariffs.' Pharma tariffs still a point of disagreement in EU-US trade deal The trade deal ironed out between the EU and the US on Sunday has more than few wrinkles remaining, chief among them: What the levy on pharmaceuticals will be. Bloomberg reports: Read more here. The trade deal ironed out between the EU and the US on Sunday has more than few wrinkles remaining, chief among them: What the levy on pharmaceuticals will be. Bloomberg reports: Read more here. Trump deal with Europe underlines new standard of (at least) 15% tariffs From YF's Ben Werschkul: Read more here. From YF's Ben Werschkul: Read more here. EU's von der Leyen provides some detail on new deal PRESTWICK, Scotland (Reuters) — European Commission President Ursula von der Leyen on Sunday said a U.S. baseline tariff rate of 15% on imported EU goods would apply to cars, semiconductors and pharmaceutical goods. She also said that a zero-for-zero tariff rate had been agreed for certain strategic products, including aircraft and aircraft parts, certain chemicals, and certain generic drugs. No decision had been taken on a rate for wine and spirits, she added. "Today's deal creates certainty in uncertain times, delivers stability and predictability," von der Leyen told reporters before leaving Scotland PRESTWICK, Scotland (Reuters) — European Commission President Ursula von der Leyen on Sunday said a U.S. baseline tariff rate of 15% on imported EU goods would apply to cars, semiconductors and pharmaceutical goods. She also said that a zero-for-zero tariff rate had been agreed for certain strategic products, including aircraft and aircraft parts, certain chemicals, and certain generic drugs. No decision had been taken on a rate for wine and spirits, she added. "Today's deal creates certainty in uncertain times, delivers stability and predictability," von der Leyen told reporters before leaving Scotland EU-US trade agreement reactions Reuters gathered some market commentary after the US and EU announced the framework of a trade deal: Read more here. Reuters gathered some market commentary after the US and EU announced the framework of a trade deal: Read more here. EU-US trade agreement preliminary details Here are some Bloomberg terminal headlines with various details on the agreement reached between President Trump and European Commission President Ursula von der Leyen: *TRUMP: WE HAVE REACHED A DEAL WITH EU *TRUMP: EU WILL AGREE TO BUY US $750B WORTH OF ENERGY *TRUMP: EU WILL AGREE TO INVEST $600B MORE THAN PREVIOUSLY IN US *EU'S VON DER LEYEN: TREADE DEAL WITH US WILL BRING STABILITY *VON DER LEYEN: AGREED TO 15% ACROSS THE BOARD TARIFFS The asserted details of the framework are not yet fully confirmed. Here are some Bloomberg terminal headlines with various details on the agreement reached between President Trump and European Commission President Ursula von der Leyen: *TRUMP: WE HAVE REACHED A DEAL WITH EU *TRUMP: EU WILL AGREE TO BUY US $750B WORTH OF ENERGY *TRUMP: EU WILL AGREE TO INVEST $600B MORE THAN PREVIOUSLY IN US *EU'S VON DER LEYEN: TREADE DEAL WITH US WILL BRING STABILITY *VON DER LEYEN: AGREED TO 15% ACROSS THE BOARD TARIFFS The asserted details of the framework are not yet fully confirmed. SCMP reports China-US another 90-day tariff extension The South China Morning Post (SCMP) reported that "Beijing and Washington are expected to extend their tariff truce by another three months at trade talks in Stockholm beginning on Monday." More from the Hong-Kong-based SCMP: Read more here. The South China Morning Post (SCMP) reported that "Beijing and Washington are expected to extend their tariff truce by another three months at trade talks in Stockholm beginning on Monday." More from the Hong-Kong-based SCMP: Read more here. Lutnick: EU has to offer Trump 'a good enough deal' to avoid 30% tariffs As President Trump prepares for a planned meeting about tariffs with European Commission President Ursula von der Leyen, Commerce Secretary Howard Lutnick said Sunday that the European Union has to open its markets for US exports if it wants to convince Trump to reduce the 30% tariff he's threatened to put in place August 1. Reuters reports Lutnick said the EU appeared to want to make a deal: On Friday, Trump said the odds of a trade deal with the EU were about "50-50," even as negotiators from both sides expressed optimism. Read more here. As President Trump prepares for a planned meeting about tariffs with European Commission President Ursula von der Leyen, Commerce Secretary Howard Lutnick said Sunday that the European Union has to open its markets for US exports if it wants to convince Trump to reduce the 30% tariff he's threatened to put in place August 1. Reuters reports Lutnick said the EU appeared to want to make a deal: On Friday, Trump said the odds of a trade deal with the EU were about "50-50," even as negotiators from both sides expressed optimism. Read more here. LG says consumers rushed to buy appliances ahead of tariffs Tariffs remain a key concern for South Korean appliance maker LG Electronics ( The company said that if President Trump's blanket tariffs take effect on Aug. 1, it will adjust prices and move some production to its plants in Mexico and the US. LG produces its products worldwide, particularly in South Korea, China, and Vietnam. On Aug. 1, imports from South Korea face a 25% tariff, while those from Vietnam face a 20% tariff. Imports from China are estimated to face tariffs of roughly 50%, though that could change after US and Chinese officials meet in Sweden for the next round of trade talks. According to LG, consumers rushed to purchase items in the first half of the year to avoid tariffs. Still, the company's net profit fell 3.1% in Q2 as operating costs increased. "Some consumers have been rushing to make purchases before the tariffs take effect," an executive said on the earnings call. "In the first half of 2025, we achieved approximately 3% growth year over year, higher than the market demand with new product launches and efficient sales operations, continuing to strengthen our market presence." But that pull-forward in demand could signal weakness ahead in the months to come if trade tensions escalate again. "A rise in product costs driven by the 50% tariff on steel and reciprocal tariffs that are set to be applied in the latter half of the year could translate into greater uncertainties for the market price," the executive said. "Additionally, shifts in the US government's trade policies and weakening consumer sentiment cast doubt on the demand outlook for home appliances." This isn't the first time LG has grappled with US protectionist policies. In 2018, during Trump's first term, washing machine prices rose when Trump targeted the industry with tariffs. Tariffs remain a key concern for South Korean appliance maker LG Electronics ( The company said that if President Trump's blanket tariffs take effect on Aug. 1, it will adjust prices and move some production to its plants in Mexico and the US. LG produces its products worldwide, particularly in South Korea, China, and Vietnam. On Aug. 1, imports from South Korea face a 25% tariff, while those from Vietnam face a 20% tariff. Imports from China are estimated to face tariffs of roughly 50%, though that could change after US and Chinese officials meet in Sweden for the next round of trade talks. According to LG, consumers rushed to purchase items in the first half of the year to avoid tariffs. Still, the company's net profit fell 3.1% in Q2 as operating costs increased. "Some consumers have been rushing to make purchases before the tariffs take effect," an executive said on the earnings call. "In the first half of 2025, we achieved approximately 3% growth year over year, higher than the market demand with new product launches and efficient sales operations, continuing to strengthen our market presence." But that pull-forward in demand could signal weakness ahead in the months to come if trade tensions escalate again. "A rise in product costs driven by the 50% tariff on steel and reciprocal tariffs that are set to be applied in the latter half of the year could translate into greater uncertainties for the market price," the executive said. "Additionally, shifts in the US government's trade policies and weakening consumer sentiment cast doubt on the demand outlook for home appliances." This isn't the first time LG has grappled with US protectionist policies. In 2018, during Trump's first term, washing machine prices rose when Trump targeted the industry with tariffs. Japan says $550 billion investment could finance Taiwanese chipmaker in US The $550 billion President Trump said Japan gave to the US "to lower their tariffs a little bit," could be used to help finance a Taiwanese chipmaker building plants in the US, the Associated Press reported Saturday. Trump on Thursday called the $550 billion "seed money" and that 90% of profits from the money invested would go to the US. "It's not a loan or anything, it's a signing bonus," Trump said. Read more here. The $550 billion President Trump said Japan gave to the US "to lower their tariffs a little bit," could be used to help finance a Taiwanese chipmaker building plants in the US, the Associated Press reported Saturday. Trump on Thursday called the $550 billion "seed money" and that 90% of profits from the money invested would go to the US. "It's not a loan or anything, it's a signing bonus," Trump said. Read more here. More cracks form in the US-Japan trade agreement We detailed earlier (keep scrolling) some initial, if gentle, pushback from the Japanese side on the US portrayal of the countries' trade deal. The Financial Times has a good, detailed look at some of the "cracks" forming: Read more here (subscription required). We detailed earlier (keep scrolling) some initial, if gentle, pushback from the Japanese side on the US portrayal of the countries' trade deal. The Financial Times has a good, detailed look at some of the "cracks" forming: Read more here (subscription required). EU head to meet with Trump this weekend in bid to clinch deal Bloomberg reports that European Commission President Ursula von der Leyen will meet with President Trump this weekend as he travels to his golf club in Scotland in a bid to secure a trade deal. The meeting will come as the two sides race to secure a deal ahead of next Friday — Trump's self-imposed deadline for 30% tariffs on EU goods to kick in. On Friday, Trump put the odds of a deal at "50-50." From the report: Bloomberg reports that European Commission President Ursula von der Leyen will meet with President Trump this weekend as he travels to his golf club in Scotland in a bid to secure a trade deal. The meeting will come as the two sides race to secure a deal ahead of next Friday — Trump's self-imposed deadline for 30% tariffs on EU goods to kick in. On Friday, Trump put the odds of a deal at "50-50." From the report: Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study
Alfasigma plans to submit data from the OLINGUITO Phase 3 clinical trial to European Medicines Agency (EMA) and UK's Medicines Healthcare products Regulatory Agency (MHRA) to seek market authorization for filgotinib in the treatment of adults with active axial spondyloarthritis (axSpA). Filgotinib, an oral, once-daily JAK1 preferential inhibitor, met the primary endpoint in the OLINGUITO Phase 3 clinical trial, demonstrating efficacy across the full spectrum of axSpA (r-axSpA and nr-axSpA). The safety profile was consistent with previous filgotinib studies, with no unexpected events observed. AxSpA is a chronic inflammatory disease primarily affecting young adults, typically emerging during the third decade of life, with only 40-50% of patients with axSpA achieving adequate response with current treatments. If approved, filgotinib would offer a new oral treatment option for patients with axSpA expanding the treatment landscape in a therapeutic area marked by significant unmet needs. BOLOGNA, Italy, July 28, 2025--(BUSINESS WIRE)--Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01),i evaluating filgotinib (marketed as Jyseleca® in approved indications) to treat adult patients with active axial spondyloarthritis (axSpA). Filgotinib, an oral, once-daily JAK1 preferential inhibitor, met the primary endpoint in the OLINGUITO Phase 3 clinical trial in active axSpA. Efficacy was demonstrated across the full spectrum of axSpA, including both radiographic (r-axSpA) and non-radiographic (nr-axSpA) forms. The safety profile was consistent with previous studies, with no unexpected events Filgotinib is currently approved for the treatment of moderate to severe active rheumatoid arthritis (RA) and ulcerative colitis (UC).iii "These positive OLINGUITO topline results demonstrate filgotinib's potential to address this critical unmet need for patients with axial spondyloarthritis, with only half responding adequately to current therapies," said Daniele D'Ambrosio, Chief Development Officer at Alfasigma. "Based on these encouraging results, we intend to submit for an extension of filgotinib's current indications, offering a potential new treatment option for patients with axial spondyloarthritis who often struggle with debilitating symptoms from a young age. We thank all patients, investigators and staff at study sites whose participation made this important achievement possible." "These results from the OLINGUITO Phase 3 clinical trial clearly support the potential of filgotinib as a treatment option for patients living with axSpA at all stages of the disease. The burden of disease for these patients remains high as treatment options are limited. It is therefore encouraging that the primary endpoint for both axSpA indications was met in dedicated studies," said Professor Xenofon Baraliakos, Head of Rheumatology at the Rheumazentrum Ruhrgebiet, Herne, Germany, Professor for Internal Medicine and Rheumatology at the Ruhr-University Bochum, Germany. AxSpA is a chronic inflammatory disease primarily affecting young adults, typically emerging during the third decade of life. It primarily affects the axial skeleton (spine and sacroiliac joints) causing significant pain, stiffness and reduced Despite several efficacious anti-inflammatory treatment options, only about 40% to 50% of patients with axSpA achieve a relevant treatment response, and an even smaller proportion (approximately 10%-20%) reach remission or an inactive disease activity state within 16 to 24 weeks of treatment initiation.v About OLINGUITO The OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01) was designed – in compliance with the European Medicines Agency's (EMA) guidelines – to evaluate the efficacy and safety of filgotinib in patients with active axial spondyloarthritis (axSpA). OLINGUITO was preceded by the TORTUGA Phase 2 clinical trial (NCT03117270), a randomized, double-blind, placebo-controlled clinical trial that demonstrated the safety and efficacy of filgotinib in adult patients with moderately to severely active ankylosing spondylitis (also known as r-axSpA, i.e., the damage caused by the disease can be seen on X-rays).vi The first patient entered the OLINGUITO Phase 3 clinical trial in April 2023. The trial consisted of two randomized, double-blind, multi-center, parallel-group studies of patients with active axSpA who had an inadequate response to conventional or biological treatments. Study A included 258 patients with r-axSpA, while study B included 237 patients with non-radiographic axSpA (nr-axSpA, i.e., the patient had symptoms of axSpA but damage was not yet visible on X-rays). After enrollment, patients in each study were randomized (1:1) to receive treatment with oral filgotinib 200 mg, or matching placebo, once daily for 16 weeks. The primary endpoint for both studies was the proportion of patients who achieved an Assessment of SpondyloArthritis international Society 40% improvement (ASAS40) at Week Thereafter, patients without risk factors entered an open-label treatment period in which they received filgotinib 200 mg once daily up to Week 52. Patients from study A and study B who achieved sustained low disease activity or inactive disease during the open-label period were re-randomized (1:1) at Week 52 to receive double-blind filgotinib 100 mg or 200 mg up to Week 104. In patients above 65 years of age and those with increased risk factors for cardiovascular disease or malignancies, at Week 16 in the case of achievement of disease control after treatment with 200 mg once daily, the dose was reduced to 100 mg once daily for up to Week 104. All patients receiving filgotinib 100 mg daily had the option to increase to 200 mg daily in case of flares. Week 52 visits for all patients were completed in May 2025. After Week 104, select eligible patients who achieve ASAS40 response without high disease activity, per investigators' judgment, will enter the Open Label Extension (OLE) study. This OLE is designed to collect additional long-term safety and efficacy data for a duration of approximately 2.5 years. About Filgotinib Filgotinib (marketed as Jyseleca®) is currently approved by the relevant regulatory authorities in the European Union, United Kingdom, Japan, Taiwan, South Korea and Singapore. In Europe, United Kingdom, Japan, Taiwan, South Korea and Singapore, filgotinib is approved for the treatment of moderate to severe active rheumatoid arthritis in adults who have not responded adequately or cannot tolerate other disease modifying anti-rheumatic drugs (DMARDs). Filgotinib is also approved in Europe, United Kingdom, Japan Taiwan, South Korea and Singapore for the treatment of adult patients with moderate to severe active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib 100mg and 200mg are registered in the above-mentioned territories. The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at The United Kingdom Summary of Product Characteristics for filgotinib can be found at The interview form from the Japanese Ministry of Health, Labor and Welfare is available at The Taiwan Food and Drug Administration Assessment Report for filgotinib can be found at The Korean Ministry of Food and Drug Safety report on filgotinib can be found here The Singapore Summary of Product Characteristics for filgotinib can be found at About axial spondyloarthritis Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that primarily affects the axial skeleton (spine and sacroiliac joints). While persistent back pain and spinal stiffness are common initial symptoms, the disease often also presents with peripheral manifestations such as enthesitis, arthritis, and dactylitis, as well as extra-musculoskeletal features including uveitis, inflammatory bowel disease and psoriasis. AxSpA comprises the whole spectrum of patients with and without radiographic sacroiliitis, that is, radiographic axSpA (r-axSpA; also known as ankylosing spondylitis, i.e., the damage caused by the disease can be seen on X-rays) and non-radiographic axSpA (nr-axSpA), respectively. AxSpA usually starts during the third decade of life; r-axSpA is more common in men than women, whereas there is an equal sex distribution among patients with About Alfasigma Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered (in Bologna and Milan). The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa. It has offices in several countries, including Italy, the US, Spain, Germany, Mexico, and China; production sites in Italy (Pomezia, RM; Alanno, PE; Sermoneta, LT; Trezzano Rosa, MI), Spain (Tortosa, Baix Ebre), and the United States (Shreveport, Louisiana); and R&D labs in Italy (Pomezia and Bergamo). Alfasigma employs approximately 4,000 people dedicated to research, development, production, and distribution of medicinal products, contributing to its mission, to provide better health and a better quality of life for patients, caregivers, and healthcare providers'. It focuses on three main therapeutic areas: Gastroenterology, Vascular and Rheumatology. Its portfolio spans from primary care to specialty care, rare disease medications, and consumer health products, including medical foods and nutraceuticals. For more information, please visit Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Alfasigma. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. Alfasigma assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References i OLINGUITO Clinical Trial (NCT05785611) Study Details | A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis | Accessed July 2025. ii The topline results of OLINGUITO Phase 3 clinical trial will become available in future scientific conferences and published in a peer-reviewed journal in due course. iii Accessed July 2025. iv Navarro-Compán V, et al., Axial spondyloarthritis. Lancet 2025; 405: 159–72 v Poddubnyy D, et al. Ann Rheum Dis 2025; 84(4): 538-546. doi: 10.1016/ vi Van der Heijde D, et al. Lancet 2018; 392(10162): 2378-2387. doi: 10.1016/S0140-6736(18)32463-2 vii J. Sieper, et al. Ann Rheum Dis. 2009 Jun:68 Suppl 2:ii1-44. doi: 10.1136/ard.2008.104018. Based on the ASAS (Assessment of SpondyloArthritis International Society) assessment that includes four aspects (domains): patient global assessment, pain, function and inflammation. In order to meet ASAS40 response, 3 of the 4 domains should improve by at least 40% with a minimum 2-unit change on a scale of 0 to 10. For the remaining domain, there should be no deterioration (worsening) from baseline. View source version on Contacts Contact Press Office:Gea Annie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Horst Mahler, a German Holocaust denier who was once a far-left militant, dies at 89
Germany Obit Mahler BERLIN (AP) — Horst Mahler, a founding member of the left-wing Red Army Faction militant group who later became a right-wing extremist and accumulated a series of convictions, including for Holocaust denial, has died, a lawyer who represented him said Monday. He was 89. Mahler died on Sunday at a hospital in Berlin, Jan Dollwetzel, who represented Mahler at a trial in 2023, told German news agency dpa. Mahler, born on Jan. 23, 1936, became a lawyer and in 1969 defended militants Andreas Baader and Gudrun Ensslin in a trial. Shortly afterward, he went on to found the Red Army Faction with them. The group, which emerged from German student protests against the Vietnam War, killed 34 people and injured hundreds of others in a violent campaign against what members considered U.S. imperialism and capitalist oppression of workers. It declared itself disbanded in 1998. In 1970, Mahler was arrested and sentenced to 14 years in prison over various bank robberies with a far-left motivation. He distanced himself from his extremist past while in custody and was released after 10 years. In 1987, he was readmitted to practice as a lawyer with the help of his then-defense attorney, Gerhard Schröder, who would later become German chancellor. In the 1990s, Mahler switched to the opposite political extreme, becoming a member of the far-right National Democratic Party for a few years. He represented the party in 2001 in its case against an unsuccessful attempt by authorities to ban it. Mahler racked up several convictions for denying the Holocaust, which earned him sentences totaling 10 years, and while in prison wrote a 200-page antisemitic screed that was put on the internet by unknown culprits. In 2017, he fled to Hungary after being ordered to return to prison following a break from serving his sentence due to serious illness. Mahler said after he was arrested that he had requested asylum, but his claim was not confirmed by authorities. He was extradited to Germany and returned to prison. Mahler was released in October 2020 and lived in Kleinmachnow, just outside Berlin. Another trial against him was shelved in April 2023 for health reasons and never resumed.